Wake research provides investigational health services to COVID patients nationwide via the newest clinical research trials
Seven Sites Now Enrolling for COVID-19 Vaccine Trials, Testing, Inpatient and Outpatient COVID Treatment Studies
(Raleigh, NC) June 10, 2020– Wake Research, a national leader in clinical research and one of the largest Phase I-IV clinical trial service companies in North America, announces the commencement of several new clinical research trials to help patient communities battle the COVID-19 pandemic, including trials for COVID vaccines, COVID diagnostic testing, and inpatient and outpatient care for patients with COVID-19. Seven Wake Research sites in six states will be participating in the trials, including North Carolina, Georgia, Tennessee, California, Nevada, and Texas.
“We are excited to be able to participate in these trials and to offer ground-breaking investigational treatment to COVID patients (inpatient and outpatient) across the country,” states Ella Grach, MD, President and Chief Executive Officer of Wake Research. “Our entire team is working diligently to assure patient safety in compliance with CDC and local public health authorities’ guidelines while maintaining the highest quality and integrity metrics, and streamlining processes to ensure the most efficient and effective patient care and recruitment rates. Our best defense against the global pandemic is efficient and well-run clinical trials providing high integrity data toward the discovery of new treatments,” she adds.
COVID Clinical Trial Locations and Patient Information
Several of the Wake Research COVID-19 clinical studies are being conducted in partnership with local hospitals, particularly for inpatient treatment of COVID patients:
Fayetteville, NC – A COVID-19 inpatient treatment trial initiated the first week of June, at the CICR site in Fayetteville, in partnership with Cape Fear Valley Hospital nearby. 1841 Quiet Cove, Suite 2, Fayetteville, NC 28304. For more information, call (910) 302-8151 or visit www.ci-cr.com. Inpatient and outpatient treatments.
Las Vegas, NV – Through Wake Research’s site in the Las Vegas area, CRCN, there will be both out-patient and inpatient COVID trials conducted in partnership with a local hospital: 1012 E Sahara Ave, Las Vegas, NV 89104. For more information, call (702) 893-8968 or visit www.crcnevada.com. Inpatient and outpatient treatments, vaccine, and COVID test.
Other locations for Wake Research COVID-19 clinical trials include:
- Raleigh, NC – Outpatient treatment, vaccine, and COVID-19 test. Wake Research site – 3100 Duraleigh Rd., Suite 304, Raleigh, NC 27612. For more information, call (919) 781-2514 or visit www.wakeclinical.com.
- Atlanta, GA – Outpatient treatment. Mount Vernon location of Wake Research. 755 Mount Vernon Highway NE, Suite 200, Atlanta, GA 30328. For more information, call (404) 419-1857 or visit mvclinical.com.
- Chattanooga, TN – Outpatient treatment. 6035 Shallowford Rd., Suite 109, Chattanooga, TN 37421. For more information, call (423) 698-4584 or visit
- San Diego, CA – COVID-19 test and outpatient treatment. 9040 Friars Rd., Suite 540, San Diego, CA 92108. For more information, call (619) 521-2841 or visit www.mccresearch.com.
- Dallas, TX – COVID-19 test and outpatient treatment. Global Medical Research. 2701 S. Hampton Rd. Suite 250, Dallas TX, 75224. For more information, call (972) 996-5645 or visit globalmedicalresearch.us.
Potential patients interested in learning more and potentially enrolling in a study may visit www.wakeclinical.com. If selected to participate in a study, patients are compensated for their time and travel.
“In addition to receiving the highest quality of care from some of the best physicians in the clinical research field, participants in these studies are contributing to the future of medicine, providing key insights and data needed to develop a treatment or vaccine for COVID-19,” Dr. Grach states. “The first wave of Covid-19 Infection in many places is getting under control. That is a great accomplishment, and it’s really crucial that we use this window of opportunity to conduct clinical trials to develop much needed treatments,” she concludes.
Wake Research is owned by M3, Inc., a global healthcare services company with businesses in more than a dozen countries, including medical research, media, and workforce/staffing services. For more information, visit https://www.wakeresearch.com.
About Wake Research, Inc.:
M3-Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. M3-Wake Research’s 16 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.
M3-Wake Research is known for effectively combining strategic volunteer recruitment, rapid trial start-up, and subject enrollment/retention with high-quality clinical trial conduct, using standardized operating procedures and centralized marketing and advertising to ensure rapid subject enrollment. M3-Wake Research sites have conducted more than 7,000 research studies for hundreds of pharmaceutical and biotech sponsors and CROs. Wake Research’s mission is to bring novel medications, biologics, and devices through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders.
About M3 Inc.:
M3 Inc. operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net, and medlive.cn. M3 Inc. is a publicly-traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including the USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, Beijing, and Seoul.